Chinese medicine and biomodulation in cancer patients - Part two

Current Oncology

Volumn 15, Issue 2, 2008, Pages 8-30

  Sagar, Stephen M ^a,b,c   Wong, R K ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Acupuncture; Chinese medicine; Herbs; Immunity; Research; Supportive care

Indexed keywords

ANEMARRHENA ASPHODELOIDES EXTRACT; ANGELICA SINENSIS EXTRACT; ANTINEOPLASTIC AGENT; ASTRAGALUS EXTRACT; ASTRAGALUS MEMBRANACEUS EXTRACT; CODONOPSIS PILOSULA EXTRACT; COPTIS RHIZOME; CORDYCEPS SINENSIS EXTRACT; GANODERMA LUCIDUM EXTRACT; GENISTEIN; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GINSENOSIDE RH 2; GLYCYRRHIZA GLABRA EXTRACT; GLYCYRRHIZIC ACID; HEDYOTIS DIFFUSA EXTRACT; HEPARIN; HERBACEOUS AGENT; LIGUSTICUM CHUANXIONG EXTRACT; LIGUSTRUM LUCIDUM EXTRACT; OPHIOPOGON ROOT; PACLITAXEL; PAEONIA RADIX; PANAX NOTOGINSENG EXTRACT; PLATINUM COMPLEX; PLATYCODON GRANDIFLORUM EXTRACT; PROTOPANAXADIOL; SALVIA MILTIORRHIZA EXTRACT; TAMOXIFEN; UNINDEXED DRUG;

ACUPUNCTURE; ADJUVANT THERAPY; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRAIN EDEMA; BREAST CANCER; CANCER CONTROL; CANCER FATIGUE; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER PAIN; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CHINESE MEDICINE; CLINICAL TRIAL; COGNITIVE DEFECT; COLON CANCER; DECREASED APPETITE; DEMENTIA; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL SYMPTOM; HEAD INJURY; HOT FLUSH; HUMAN; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MEMORY DISORDER; MENOPAUSAL SYNDROME; METASTASIS INHIBITION; NASOPHARYNX CARCINOMA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NONHUMAN; OVERALL SURVIVAL; RADIOSENSITIVITY; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 54349085371     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v15i2.238     Document Type: Review

References (317)

1. Coffey DS. Self-organization, complexity and chaos: the new biology for medicine. Nature Med 1998;4:882-5.
2. Cuzick J, Holland R, Barth V, et al. Electropotential measurements as a new diagnostic modality for breast cancer. Lancet 1998;352:359-63.
3. 2. Cancer Lett 2000; 152:97-106.
4. Sagar SM, Klassen GA, Barclay KD, Aldrich JE. Tumour blood flow: measurement and manipulation for therapeutic gain. Cancer Treat Rev 1993;19:299-349.
5. Milosevic MF, FyIes AW, Wong F, et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 1998;82:2418-26.
6. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 1989;37:77-104.
7. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
8. Fyles AW, Milosevic M, Wong F, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-56.
9. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994;74:38-45.
10. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999;91:22-36.
11. Yance DR, Sagar SM. Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther 2006;5:9-29.
12. Wang JZ, Tsumura H, Shimura K, Ito H. Antitumor activity of polysaccharide from a Chinese medicinal herb, Acanthopanax giraldii Harms. Cancer Lett 1992;65:79-84.
13. Tode T, Kikuchi Y, Kita T, Hirata J, Imaizumi E, Nagata I. Inhibitory effects by oral administration of ginsenoside Rh2 on the growth of human ovarian cancer cells in nude mice. J Cancer Res Clin Oncol 1993;120:24-6.
14. Lau BH, Ruckle HC, Botolazzo T, Lui PD. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma. Cancer Biother 1994;9:153-61.
15. Boik J. Cancer and Natural Medicine: A Textbook of Basic Science and Clinical Research. Rev ed. Princeton, MN: Oregon Medical Press; 1996.
16. Boik J. Emerging trends in cancer research: development of a mechanism-based approach. Protocol J Botanic Med 1996; 2:5-10.
17. Shoemaker M, Hamilton B, Dairkee SH, Cohen I, Campbell MJ. In vitro anticancer activity of twelve Chinese medicinal herbs. Phytother Res 2005;19:649-51.
18. Xu GZ, Cai WM, Qin DX, et al. Chinese herb "destagnation" series I: combination of radiation with destagnation in the treatment of nasopharyngeal carcinoma (NPC): a prospective randomized trial on 188 cases. Int J Radiat Oncol Biol Phys 1989;16:297-300.
19. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:1136-9.
20. Ha SW, Yi CJ, Cho CK, Cho MJ, Shin KH, Park CI. Enhancement of radiation effect by Ginkgo biloba in C3H mouse fibrosarcoma. Radiother Oncol 1996;41:163-7.
21. Sagar SM, Singh G, Hodson DI, Whitton AC. Nitric oxide and anti-cancer therapy. Cancer Treat Rev 1995;21:159-81.
22. Kuang P, Tao Y, Tian Y. Radix Salving miltiorrhizae treatment results in decreased lipid peroxidation in reperfusion injury. J Tradit Chin Med 1996;16:138-42.
23. Sun H, Duan S, Yu G. Free radical mechanism in enhancement of radiosensitization by saser. J Tradit Chin Med 1994;14:51-5.
24. Lee TK, Johnke RM, Allison RR, O'Brien KF, Dobbs LJ Jr. Radioprotective potential of ginseng. Mutagenesis 2005;20: 237-43.
25. Zhou RF, Liu PX. Study progress in reversing multidrug resistance to breast cancer with Chinese herbs [Chinese]. Zhongguo Zhong Yao Za Zhi 2005;30:1797-800.
26. Kang JX, Liu J, Wang J, He C, Li FP. The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-β and TNF-α in human breast cancer cells. Carcinogenesis 2005;26:1934-9.
27. Taixiang W, Munro AJ, Guanjian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev 2005;(1): 1465185 8.CD004540.pub2.
28. Shu X, McCulloch M, Xiao H, Broffman M, Gao J. Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integr Cancer Ther 2005;4:219-29.
29. Shin HJ, Kim YS, Kwak YS, Song YB, Kim YS, Park JD. Enhancement of antitumor effects of paclitaxel (Taxol) in combination with red ginseng acidic polysaccharide (RGAP). Planta Med 2004;70:1033-8.
30. Collins L, Zhu T, Guo J, Xiao ZJ, Chen, CY. Phellinus linteus sensitises apoptosis induced by doxorubicin in prostate cancer. Br J Cancer 2006;95:282-8.
31. McCulloch M, See C, Shu XJ, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006;24:419-30.
32. Liang HL, Xue CC, Li CG. Regression of squamous cell carcinoma of the lung by Chinese herbal medicine: a case with an 8-year follow-up. Lung Cancer 2004;43:355-60.
33. Lee YJ, Jin YR, Lim WC, et al. Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. Arch Pharm Res 2003;26:58-63.
34. Amato P, Christophe S, Mellon PL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause 2002;9:145-50.
35. Chang CJ, Chiu JH, Tseng LM, et al. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. Eur J Clin Invest 2006;36:588-96.
36. Campbell MJ, Hamilton B, Shoemaker M, Tagliaferri M, Cohen I, Tripathy D. Antiproliferative activity of-Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res 2002;22:3843-52.
37. Jia WW, Bu X, Philips D, et al. Rh2, a compound extracted from ginseng, hypersensitizes; multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 2004;82:431-7.
38. Loo WT, Cheung MN, Chow LW. The inhibitory effect of a herbal formula comprising ginseng and Carthamus tinctorius on breast cancer. Life Sci 2004;76:191-200.
39. Yu Y, Zho-u Q, Hang Y, Bu X, Jia W. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells. Cancer 2007;109:2374-82.
40. King ML, Murphy LL. American ginseng (Panax quinquefolius L.) extract alters mitogen-activated protein kinase cell signaling and inhibits proliferation of MCF-7 cells. J Exp Ther Oncol 2007;6:147-55.
41. Aung HH, Mehendale SR, Wang CZ, Xie JT, McEntee E, Yuan CS. Cisplatin's tumoricidal effect on human breast carcinoma-MCF-7 cells was not attenuated by American ginseng. Cancer Chemother Pharmacol 2007;59:369-74.
42. Piersen CE. Phytoestrogens in botanical dietary supplements: implications for cancer. Integrat Cancer Ther 2003;2:120-38.
43. Sagar SM. Future directions for research on Silybum marianum for cancer patients. Integr Cancer Ther 2007;6:166-73.
44. Lau CB, Ho TC, Chan TW, Kim SC. Use of dong quai (Angelica sinensis) to treat peri-or postmenopausal symptoms in women with breast cancer: is it appropriate? Menopause 2005;12:734-40.
45. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 1997;68:981-6.
46. Duda RB, Zhong Y, Navas V, Li MZ, Toy BF, Alavarez JG. American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol 1999;72:230-9.
47. King ML, Adler SR, Murphy LL. Extraction-dependent effects of American ginseng (Panax quinquefolium) on human breast cancer cell proliferation and estrogen receptor activation. Integr Cancer Ther 2006;5:236-43.
48. Cui Y, Shu XO, Gao YT, Cai H, Tho MH, Zheng W. Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol 2006;163:645-53.
49. Barton DL, Soori GS, Bauer B, et al. A pilot, multi-dose, placebo-controlled evaluation of American ginseng (Panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA [abstract 900 11. J Clin Oncol 2007;25:18S.
50. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998;339:785-91.
51. Guns ES, Goldenberg SL, Brown PN. Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol. Can J Urol 2002;9:1684-8.
52. Oh WK, Kantoff PW, Weinberg V, et al. Prospective, multicenter randomized phase II trial of the herbal supplement: PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004;22:3705-12.
53. Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 1998;68:1418S-25S.
54. Li Y, Bhuiyan M, Sarkar FH. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB435 cells by genistein. Int J Oncol 1999;15:525-33.
55. Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 1999;18:3166-72.
56. Wu AH, Ziegler RG, Horn-Ross PL, et al. Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiol Biomarkers Prev 1996;5:901-6.
57. Witte JS, Ursin G, Siemiatycki J, Thompson WD, Paganini-Hill A, Haile RW. Diet and premenopausal bilateral breast cancer: a case-control study. Breast Cancer Res Treat 1997;42:243-51.
58. Lu LJ, Cree M, Josyula S, Nagamani M, Grady JJ, Anderson KE. Increased urinary excretion of 2-hydroxyestrone but not 16α-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res 2000;60:1299-305.
59. Key TJ, Sharp GB, Appleby PN, et al. Soya foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 1999;81:1248-56.
60. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998;58:3833-8.
61. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 2000;7:105-11.
62. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18:1068-74.
63. MacGregor CA, Canney PA, Patterson G, McDonald R, Paul J. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 2005;41:708-14.
64. Hu SA. Risks and benefits of soy isoflavones for breast cancer survivors. Oncol Nurs Forum 2004;31:249-63.
65. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 2006;98:1275-84.
66. Spence DW, Kayumov L, et al. Acupuncture increases nocturnal melatonin secretion and reduces insomnia and anxiety: a preliminary report. J Neuropsychiatry Clin Neurosci 2004; 16:19-28.
67. Stener-Victorin E, Lundeberg T, Waldenstrom U, Bileviciute-Ljungar I, Janson PO. Effects of electro-acupuncture on corticotropin-releasing factor in rats with experimentally-induced polycystic ovaries. Neuropeptides 2001;35:227-31.
68. Ning CH, Wang GM, Zhao TY, Yu GQ, Duan FW. Therapeutical effects of jian pi yi shen prescription on the toxicity reactions of postoperative chemotherapy in patients with advanced gastric carcinoma. J Tradit Chin Med 1988;8:113-16.
69. Chen JZ. Clinical effect of chemotherapy combined with Chinese herbs and western drugs on leukocytes of gastric cancer patients [Chinese]. Zhong Xi Yi Jie He Za Zhi 1990;10:717-19.
70. Yu RC, Guan CF, Zhang JH. Immune function of cancer patients with spleen-deficiency syndrome [Chinese]. Zhong Xi Yi Jie He Za Zhi 1990;10:535-7,516.
71. Hou J, Liu S, Ma Z, et al. Effects of Gynostemma pentaphyllum makino on the immunological function of cancer patients. J Tradit Chin Med 1991;11:47-52.
72. Rao XQ, Yu RC, Zhang JH. Sheng xue tang on immunological functions of cancer patients with spleen-deficiency syndrome [Chinese]. Zhong Xi Yi Jie He Za Zhi 1991;11:218-19.
73. Li NQ. Clinical and experimental study on shen-qi injection with chemotherapy in the treatment of malignant tumor of digestive tract [Chinese]. Zhongguo Zhong Xi Yi Xe He Za Zhi 1992;12:588-92.
74. Yu G, Ren D, Sun G, Zhang D. Clinical and experimental studies of JPYS in reducing side-effects of chemotherapy in late-stage gastric cancer. J Tradit Chin Med 1993;13:31-7.
75. Cao GW, Yang WG, Du P. Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients (Chinese]. Zhonghua Zhong Liu Za Zhi 1994;16:428-31.
76. Cheng JH. Clinical study on prevention and treatment to chemotherapy caused nephrotoxicity with jian-pi yi-qi li-shui decoction [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1994;14:331-3.
77. Horie Y, Kato K, Kameoka S, Hamano K. Bu ji (hozai) for treatment of postoperative gastric cancer patients. Am J Chin Med 1994;22:309-19.
78. Lin SY, Liu LM, Wu LC. Effects of Shenmai injection on immune function in stomach cancer patients after chemotherapy [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15:451-3.
79. Pan MJ, Li YH, Chen LF. Long-term curative effect of 150 cases of nasopharyngeal cancer treated with fu zheng sheng jin decoction and radiotherapy [Chinese]. Zhong Xi Yi Jie He Za Zhi 1985;5:83-5.
80. Wang GT. Treatment of operated late gastric carcinoma with prescription of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy: follow-up study of 158 patients and experimental study in animals [Chinese]. Zhong Xi Yi Jie He Za Zhi 1990;10:712-16.
81. Kawakita T, Nakai S, Kumazawa Y, Miura O, Yumioka E, Nomoto K. Induction of interferon after administration of traditional Chinese medicine, xiao-chai-hu-tang (shosaiko-to). Int J Immunopharmacol 1990; 12:515-21.
82. Jin R, Wan LL, Mitsuishi T, et al. Effect of shi-ka-ron and Chinese herbs on cytokine production of macrophage in immunocompromised mice. Am J Chin Med 1994;22:255-66.
83. Feng PF, Liu LM, Shen YY. Effect of shenmai injection on SIL-2R, NK and LAK cells in patients with advanced carcinoma. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15:87-9.
84. Zhu H, Zhang J. Treatment of stomatological complications in 31 cases of acute leukemia with Chinese herbal drugs. J Tradit Chin Med 1993;13:253-6.
85. Zhu BF. Observation on 17 patients with radio-ulcer with combined traditional Chinese medicine and Western medicine therapy [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1994;14:89-91,68-9.
86. Whiteside LT. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006;16:3-15.
87. Berczi I, Chow DA, Baral E, Nagy E. Neuroimmunoregulation and cancer [review]. Int J Oncol 1998;13:1049-60.
88. Beuth J, Ko HL, Schirrmacher V, Uhlenbruck G, Pulverer G. Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan. Clin Exp Metastasis 1988;6:115-20.
89. Kebudi R, Ayan I, Darendeliler E, et al. Immunologic status in children with brain tumors and the effect of therapy. J Neurooncol 1995;24:219-27.
90. Vuckovic-Dekic LJ, Susnjar S, Stanojevic-Bakic N, Rajner L, Frim O. The protective, activity of Thymex L against radiotherapeutically-induced cellular immunodepression in lung cancer patients. Neoplasma 1992;39:171-6.
91. Maier H, Daniel V, Heimlich F, Frank C, Opelz G. Cellular immune defect caused by postoperative irradiation in patients with squamous epithelial carcinomas of the upper aerodigestive tract [German]. HNO 1995;43:364-70.
92. Miyazaki K, Mizutani H, Katabuchi H, Fukuma K, Fujisaki S, Okamura H. Activated (HLA-DR+) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival. Gynecol Oncol 1995;56:412-20.
93. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol 2006;16:80-8.
94. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-99.
95. Wichmann MW, Meyer G, Adam M, et al. Detrimental immunologic effects of preoperative chemoradiotherapy in advanced rectal cancer. Dis Colon Rectum 2003;46:875-87.
96. Bang S, Kim HS, Choo YS, Park SW, Chung JB, Song SY. Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer. Pancreas 2006;32:29-36.
97. Koukourakis MI, Ktenidou-Kartali S, Bourikas G, Kartalis G, Tsatalas C. Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients. Cancer Immunol Immunother 2003;52:127-31.
98. Stevenson FK. Update on cancer vaccines. Curr Opin Oncol 2005;17:573-7.
99. Minev BR. Melanoma vaccines. Semin Oncol 2002;29:479-93.
100. Hoffmann TK, Bier H, Whiteside TL. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2004;53:1055-67.
101. Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 2006;16:32-7.
102. Sen G, Khan AQ, Chen Q, Snapper CM. In vivo humoral immune responses to the isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands. J Immunol 2005; 175:3084-91.
103. Rezaei N. Therapeutic targeting of pattern-recognition receptors. Int Immunopharmacol 2006;6:863-9.
104. Heine H, Ulmer AJ. Recognition of bacterial products by Toll-like receptors. Chem Immunol Allergy 2005;86:99-119.
105. Chang R. Bioactive polysaccharides from traditional Chinese medicine herbs as anticancer adjuvants. J Altern Complement Med 2002;8:559-65.
106. Zeng F, Hon CC, Sit WH, et al. Molecular characterization of Coriolus versicolor PSP-induced apoptoais in human promyelotic leukemic HL-60 cells using CDNA microarray. Int J Oncol 2005;27:513-23.
107. Ito K, Nakazato H, Koike A, et al., for the Study Group of Immunochemotherapy with PSK for Colon Cancer. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis 2004;19:157-64.
108. Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral tegafur/uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 2004;90:1003-10.
109. Koda K, Miyazaki M, Sarashina H, et al. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. Int J Oncol 2003;23:165-72.
110. Tsang KW, Lam CL, Yan C, et al. Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer. Respir Med 2003;97:618-24.
111. Kanazawa M, Mori Y, Yoshihara K, et al. Effect of PSK on the maturation of dendritic cells derived from human peripheral blood monocytes. Immunol Lett 2004;91:229-38.
112. Wong CK, Tse PS, Wong EL, Leung PC, Fung KP, Lam CW. Immunomodulatory effects of yun zhi and danshen capsules in healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. Int Immunopharmacol 2004;4:201-11.
113. Wong CK, Bao YX, Wong EL, Leung PC, Fung KP, Lam CW. Immunomodulatory activities of yunzhi and danshen in post-treatment breast cancer patients. Am J Chin Med 2005;33:381-95.
114. Munemoto Y, Iida Y, Abe J, et al. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: association between host or tumor factors and survival. Int J Oncol 2002;20:403-11.
115. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev 1997;21:71-7.
116. Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol 1995;18:216-22.
117. Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 1992;35:123-30.
118. Nakazato H, Hoike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer; Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994;343:1122-6.
119. Shao BM, Dai H, Xu W, Lin ZB, Gao XM. Immune receptors for polysaccharides from Ganoderma lucidum. Biochem Biophys Res Commun 2004;323:133-141.
120. Lin ZB. Cellular and molecular mechanisms of immunomodulation by Ganoderma lucidum. J Pharmacol Sci 2005; 99:144-53.
121. Kuo MC, Weng CY, Ha CL, Wu MJ. Ganoderma lucidum mycelia enhance innate immunity by activating NF-KB. J Ethnopharmacol 2006;103:217-22.
122. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide entract) on the immune functions in advanced-stage cancer patients. Immunol Invest 2003;32:201-15.
123. Kodama N, Asakawa A, Inui A,Masuda Y, Nanba H. Enhancement of cytotoxicity of NK cells by D-Fraction, a polysaccharide from Grifola frondosa. Oncol Rep 2005;13:497-502.
124. Kodama N, Komuta K, Nanba H. Effect of maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients. J Med Food 2003;6:371-7.
125. Kodama N, Murata Y, Asakawa A, et al. Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice. Nutrition 2005;21:624-9.
126. Kodama N, Komuta K, Nanba H. Can maitake MD-Fraction aid cancer patients? Altern Med Rev 2002;7:236-9.
127. Inoue A, Kodama N, Nanba H. Effect of maitake (Grifola frondosa) D-Fraction on the control of the T lymph node Th1/Th-2 proportion. Biol Pharm Bull 2002;25:536-40.
128. Shao BM, Xu W, Dai H, Tu P, Li Z, Gao XM. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb. Biochem Biophys Res Commun 2004;320:1103-11.
129. Shin HJ, Kim YS, Kwak YS, Song YB, Kim YS, Park JD. Enhancement of antitumor effects of paclitaxel (Taxol) in combination with red ginseng acidic polysaccharide (RGAP). Planta Med 2004;70:1033-8.
130. Shin JY, Song JY, Yun YS, Yang HO, Rhee DK, Pyo S. Immunostimulating effects of acidic polysaccharides extract of Panax ginseng on macrophage function. Immunopharmacol Immunotoxicol 2002;24:469-82.
131. Han SK, Song JY, Yun YS, Yi SY. Ginsan improved Th1 immune response inhibited by gamma radiation. Arch Pharm Res 2005;28:343-50.
132. Lim TS, Na K, Choi EM, Chung JY, Hwang JK. Immunomodulating activities of polysaccharides isolated from Panax ginseng. J Med Food 2004;7:1-6.
133. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem 2000; 7:715-29.
134. Zaidman BZ, Yassin M, Mahajna J, Wasser SP. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol 2005;67:453-68.
135. Lindequist U, Niedermeyer TH, Julich WD. The pharmacological potential of mushrooms. Evid Based Complement Alternat Med 2005;2:285-99.
136. Han SB, Yoon YD, Ahn HJ, et al. Toll-like receptor-mediated activation of B cells and macrophages by polysaccharide isolated from cell culture of Acanthopanax senticosus. Int Immunopharmacol 2003;3:1301-12.
137. Schepetkin IA, Quinn MT. Botanical polysaccharides: macrophage immunomodulation and therapeutic potential. Int Immunopharmacol 2006;6:317-33.
138. Kabelitz D, Wesch D, Oberg HH. Regulation of regulatory T cells: role of dendritic cells and Toll-like receptors. Crit Rev Immunol 2006;26:291-306.
139. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-32.
140. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21.
141. Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004;53:79-85.
142. Wang RF. Regulatory T cells and Toll-like receptors in cancer therapy. Cancer Res 2006;66:4987-90.
143. Bartz H, Avalos NM, Baetz A, Heeg K, Dalpke AH. Involvement of suppressors of cytokine signaling in Toll-like receptor-mediated block of dendritic cell differentiation. Blood 2006;108:4102-8.
144. Garay RP, Viens P, Bauer J, et al. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007;563:1-17.
145. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
146. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 2007;67:1326-34.
147. Turnbull JL, Patchen ML, Scadden DT. The polysaccharide, PGG-glucan, enhances human myelopoiesis by direct action independent of and additive to early-acting cytokines. Acta Haematol 1999;102:66-71.
148. Ahn JY, Choi IS, Shim JY, et al. The immunomodulator ginsan induces resistance to experimental sepsis by inhibiting Toll-like receptor-mediated inflammatory signals. Eur J Immunol 2006;36:37-45.
149. Cheung NK, Modak S, Vickers A, Knuckles B. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 2002;51:557-64.
150. Koski GK, Czerniecki BJ. Combining innate immunity with radiation therapy for cancer treatment. Clin Cancer Res 2005;11:7-11.
151. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005;63:655-66.
152. United States, National Institutes of Health, ClinicalTrials.gov. Beta-Glucan and rituximab in treating young patients with relapsed or progressive lymphoma or leukemia, or lymphoproliferative disorder related to donor stem cell transplantation [Web page]. Bethesda: National Institutes of Health; 2006. [Available at: www.clinicaltrials.gov/ct/gui/show/NCT00087009; cited July 2007]
153. Chan WL, Lam DT, Law HK, et al. Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy. J Altern Complement Med 2005;11:1047-57.
154. Bianchi M, Jotti E, Sacerdote P, Panerai AE. Traditional acupuncture increases the content of beta-endorphin in immune cells and influences mitogen induced proliferation. Am J Chin Med 1991;19:101-4.
155. Yuan J, Zhou R. Effect of acupuncture on T-lymphocyte and its subsets from the peripheral blood of patients with malignant neoplasm [Chinese]. Zhen Ci Yan Jiu 1993;18:174-7.
156. Wu B, Zhou RX, Zhou MS. Effect of acupuncture on interleukin-2 level and NK cell immunoactivity of peripheral blood of malignant tumor patients [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1994;14:537-9.
157. Wu B, Zhou RX, Zhou MS. Effect of acupuncture on immunomodulation in patients with malignant tumors [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1996;16:139-41.
158. Yang J, Zhao R, Yuan J, et al. The experimental study of prevention and treatment of the side-effects of chemotherapy with acupuncture (comparison among the effect of acupuncture at different acupoints) [Chinese]. Zhen Ci Yan Jiu 1994; 19:75-8.
159. Liu LJ, Guo CJ, Jiao XM. Effect of acupuncture on immunologic function and histopathology of transplanted mammary cancer in mice. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15:615-17.
160. Sato T, Yu Y, Guo SY, Kasahara T, Hisamitsu T. Acupuncture stimulation enhances splenic natural killer cell cytotoxicity in rats. Jpn J Physiol 1996;46:131-6.
161. Petti F, Bangrazi A, Liguori A, Reale G, Ippoliti F. Effects of acupuncture on immune response related to opioid-like peptides. J Tradit Chin Med 1998;18:55-63.
162. Zhou JQ, Li ZH, Jin PL. A clinical study on acupuncture for prevention and treatment of toxic side-effects during radiotherapy and chemotherapy. J Tradit Chin Med 1999; 19:16-21.
163. Lu W, Hu D, Dean-Clower E, et al. Acupuncture for chemotherapy-induced leukopenia: exploratory meta-analysis of randomized controlled trials. J Soc Integrat Oncol 2007;5:1-10.
164. Tang ZY. Hepatocellutar carcinoma. J Gastroenterol Hepatol 2000;15(suppl):G1-7.
165. Gao JD, Shao YF, Xu Y, et al. Tight association of hepatocellular carcinoma with HBV infection in North China. Hepatobiliary Pancreat Dis Int 2005;4:46-9.
166. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and c virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005;92:607-12.
167. Cheng WM, Chan KH, Chen HL, et al. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 2002;97:489-92.
168. Zong Y, Liu K, Zhong B, Chen G, Wu W. Epstein-Barr virus infection of sinonasal lymphoepithelial carcinoma in Guangzhou. Chin Med J 2001;114:132-6.
169. Jarett RF. Risk factors for Hodgkin's lymphoma by EVB status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin's lymphoma. Leuk Lymphoma 2003;44(suppl 3):S27-32.
170. Lo YM, Chan WY, Ng EK, et al. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res 2001;7:1856-9.
171. Ng WT, Yau TY, Yung RW, et al. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 2005;113:998-1001.
172. Li H, Zhao M, Qiu X, Ding X, Tan Y, Wu X. Characterization of a new type HPV16 E7 variant isolated from cervical cancer highest incidence area in Hubei province of China. Eksp Onkol 2004;26:48-54.
173. Chang F, Syrjänen S, Shen Q, et al. Evaluation of HPV, CMV, HSV and EBV in esophageal squamous cell carcinomas from a high-incidence area of China. Anticancer Res 2000;20:3935-40.
174. Li T, Lu ZM, Chen KN, et al. Human papillomavirus type 16 is an important infectious factor in the high incidence of esophageal cancer in Anyang area of China. Carcinogenesis 2001;22:929-34.
175. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000,89:300-4.
176. Almadori G, Galli J, Cadoni G, Bussu F, Maurizi M. Human papillomavirus
177. Yu Y, Morimoto T, Sasa M, et al. Human papillomavirus type 33 DNA in breast cancer in Chinese. Breast Cancer 2000;7:33-6.
178. Cheng HM, Tsai MC. Regression of hepatocellular carcinoma spontaneous or herbal medicine related? Am J Chin Med 2004; 32:579-85.
179. Yun TK, Choi SY, Yun HY. Epidemiological study on cancer prevention by ginseng: are all kinds of cancers preventable by ginseng? J Korean Med Sci 2001;16(suppl):S19-27.
180. Zhong L, Goldberg MS, Gao YT, Hanley JA, Parent ME, Jin F. A population-based case-control study of lung cancer and green tea consumption among women living in Shanghai, China. Epidemiology 2001;12:695-700.
181. Sinclair S. Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. Altern Med Rev 1998;3:338-44.
182. Block KI, Mead MN. Immune system effects of echinacea, ginseng, and astragalus: a review. Integr Cancer Ther 2003; 2:247-67.
183. Qian ZH, Vermund SH, Wang N. Risk of HIV/AIDS in China: subpopulations of special importance. Sex Transm Infect 2005;81:442-7. [Erratum in: Sex Transm Infect 2006;82:93]
184. Wu JA, Attele AS, Zhang L, Yuan CS. Anti-HIV activity of medicinal herbs: usage and potential development. Am J Chin Med 200l;29:69-81.
185. Tani M, Nagase M, Nishiyama T, Yamamoto T, Matusa R. The effects of long-term herbal treatment for pediatric AIDS. Am J Chin Med 2002;30:51-64.
186. Matsui Y, Uhara J, Satoi S, et al. Improved prognosis of post-operative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol 2002; 37:78-86.
187. Lin H, She YH, Cassileth BF, Sirotnak F, Cunningham Rundles S. Maitake β-glucan MD-Fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro. Int Immunopharmacol 2004; 4:91-9.
188. Fullerton SA, Samadi AA, Torterelis DG, et al. Induction of apoptosis in human prostatic cancer cells with beta-glucan (Maitaki mushroom polysaccharide). Molec Urol 2000;4:7-13.
189. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-KB signaling. Nutr Cancer 2004;49:209-16.
190. Sliva D. Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther 2003;2:358-64.
191. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993;85:1038-49.
192. Kaegi E. Unconventional therapies for cancer 2. Green tea. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 1998;158:1033-5.
193. Yun TY, Chol SY. Non-organ specific cancer prevention of ginseng: a prospective study in Korea. Int J Epidemiol 1998;27:359-64.
194. McKenna DJ, Hughes K, Jones K. Green tea monograph. Altern Ther Health Med 2000;6:61-8,70-2,74 passim.
195. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature 1999;398:381.
196. Fujiki H, Suganuma M, Okabe S, et al. Mechanistic findings of green tea as cancer preventive for humans. Proc Soc Exp Biol Med 1999;220:225-8.
197. Lee YN, Lee HY, Chung HY, et al. In vitro induction of differentiation by ginsenosides in F9 teratocarcinoma cells. Eur J Cancer 1996;32A:1420-8.
198. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998;9:553-7.
199. Kamat AM, Lamm DL. Chemoprevention of urological cancer. J Urol 1999;161:1748-60.
200. Moyad MA. Soy, disease prevention, and prostate cancer. Semin Urol Oncol 1999;17:97-102.
201. Stephens FO. The rising incidence of breast cancer in women and prostate cancer in men. Dietary influences: a possible preventive role for nature's sex hormone modifiers - the phytoestrogens (review). Oncol Rep 1999;6:865-70.
202. Adlercreutz H, Mazur W, Bartels P, et al. Phytoestrogens and prostate disease. J Nutr 2000;130:658S-9S.
203. Aronson WJ, Tymchuk CN, Elashoff RM, et al. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer 1999;35:130-6.
204. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-κ B activation in prostate cancer cells. Nutr Cancer 1999;35:167-74.
205. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 1999;129:1628-35.
206. Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH. Inhibition of prostate specific antigen by genistein in prostate cancer cells. Int J Oncol 2000;16:1091-7.
207. United States, National Institutes of Health, National Cancer Institute. Notes. CAM scientist tests lung cancer herb. NCI Cancer Bull 2006;3(7):7. [Available online at: www.cancer.gov/NCICancerBulletin/ NCI_Cancer_Bulletin_021406.pdf; cited October 28, 2007]
208. Cui Y, Shu XO, Gao YT, Cai H, Tao MH, Zheng W. Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol 2006;163:645-53.
209. Mowrey DB, Clayson DE. Motion sickness, ginger, and psychophysics. Lancet 1982;1:655-7.
210. Grøntved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness. A controlled trial on the open sea. Acta Otolaryngol 1988;105:45-9.
211. Grøntved A, Hentzer E. Vertigo-reducing effects of ginger root. A controlled clinical study. ORL J Otorhinolaryngol Relat Spec 1986;48:282-6.
212. Bone ME, Wilkinson DJ, Young JR, McNeil J, Charlton S. Ginger root - a new antiemetic. The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. Anaesthesia 1990;45:669-71.
213. Fischer-Rasmussen W, Kjaer SK, Dahl C, Asping U. Ginger treatment of hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol 1991;38:19-24.
214. Keating A, Chez RA. Ginger syrup as an antiemetic in early pregnancy. Altern Ther Health Med 2002;8:89-91.
215. Hien TV, Huong NB, Hung PM, Duc NB. Radioprotective effects of vitexina for breast cancer patients undergoing radiotherapy with cobalt-60. Integrat Cancer Ther 2002;1:38-43.
216. Ling HY, Wang NZ, Zhu HZ. Preliminary study of traditional Chinese medicine-Western medicine treatment of patients with primary liver carcinoma [Chinese]. Zhong Xi Yi Jie He Za Zhi 1989;9:348-9.
217. Mok TS, Yeo W, Johnson PJ, et al. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol 2007;18:768-74.
218. Zhang M, Liu X, Li J, He L, Tripathy D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev 2007;(2):14651858. CD004921.pub2.
219. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695-701.
220. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-50.
221. Meyers CA, Abbruzzese JL. Cognitive functioning in cancer patients: effect of previous treatment. Neurology 1992;42.434-6.
222. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003;12:612-19.
223. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22:2233-9.
224. Fan HG, Houédé-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005;23:8025-32.
225. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. "Chemobrain" in breast carcinoma? A prologue. Cancer 2004;101:466-75.
226. Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 2004; 90:1691-6.
227. Taphoorn MJB, Schiphorst AK, Snoek FJ, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 1994;36:48-54.
228. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004;3:159-68.
229. Taylor BV, Buckner JC, Cascino TL, et al. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol 1998;16:2195-201.
230. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003;18:S23-32.
231. van Beek TA. Ginkgolides and bilobalide: their physical, chromatographic and spectroscopic properties. Bioorg Med Chem 2005;13:5001-12.
232. Strømgaard K, Nakanishi K. Chemistry and biology of terpene trilactones from Ginkgo biloba. Angew Chem Int Ed Engl 2004;43:1640-58.
233. Biber A. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 2003;36(suppl 1):S32-7.
234. Menku A, Koc RK, Tayfur V, Saraymen R, Narin F, Akdemir H. Effects of mexiletine, Ginkgo biloba extract (EGb 761), and their combination on experimental head injury. Neurosurg Rev 2003;26:288-91.
235. Defeudis FV. Bilobalide and neuroprotection. Pharmacol Res 2002;46:565-8.
236. DeFeudis FV, Papadopoulos V, Drieu K. Ginkgo biloba extracts and cancer: a research area in its infancy. Fundam Clin Pharmacol 2003;17:405-17.
237. Ahlemeyer B, Krieglstein J. Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsychiatry 2003;36(suppl 1):S8-14.
238. Bressler R. Herb-drug interactions: interactions between Ginkgo biloba and prescription medications. Geriatrics 2005;60:30-3.
239. Santos RF, Galduroz JC, Barbieri A, Castiglioni ML, Ytaya LY, Bueno OF. Cognitive performance, SPECT, and blood viscosity in elderly non-demented people using Ginkgo biloba. Pharmacopsychiatry 2003;36:127-33.
240. Hu B, Sun S, Mei G, Chen L, Tong E. Protective effects of Ginkgo biloba extract on rats during cerebral ischemia/reperfusion. Chin Med J (Engl) 2002;115:1316-20.
241. Wang YS, Xu L, Ma K, Wang S, Wang JJ. Protective effects of Ginkgo biloba extract 761 against glutamate-induced neurotoxicity in cultured retinal neuron. Chin Med J (Engl) 2005; 118:948-52.
242. A receptors. J Biol Chem 2003;278:49279-85.
243. Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003;36:297-303.
244. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002;(4): 14651858.CD003120.pub2.
245. van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 2003;56:367-76.
246. Kurz A, Van Baelen B. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the Cochrane collaboration. Dement Geriatr Cogn Disord 2004;18:217-26.
247. Shaw EG. A phase II study of Ginkgo biloba in irradiated brain tumor patients: effects on quality of life and cognitive function [abstract 61]. In: Society for Integrative Oncology (SIO). Online program planner for the 2nd International Conference; November 10-12, 2005; San Diego, CA [Web tool]. Mt. Royal, NJ: SIO; n.d. [Available by key word search at: www.abstracts online.com/viewer/ ?mkey=%7B52C9E2CA%2D010B% 2D4l49%2D9D7C%2DD25107EF113A%7D; cited October 28, 2007]
248. Shaw EG. Phase II studies of donepezil and Ginkgo biloba in irradiated brain tumor patients. Research base protocol CCCWFU 97100. Winston-Salem, NC: Comprehensive Cancer Center, Wake Forest University; 2000. [Available online at: www1. wfubmc.edu/NR/rdonlyres/ 4A8DC232-84E1-41401-B673- C6C1617A9BD2/0/97100Am4protocol.pdf; cited July 3,2007]
249. Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 2004;95:153-7.
250. Kim S, Ahn K, Oh TH, Nah SY, Rhim H. Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem Biophys Res Commun 2002; 296:247-54.
251. Kim S, Rhim H. Ginsenosides inhibit NMDA receptor-mediated epileptic discharges in cultured hippocampal neurons. Arch Pharm Res 2004;27:524-30.
252. Kim S, Kim T, Ahn K, Park WK, Nah SY, Rhim H. Ginsenoside Rg3 antagonizes NMDA receptors through a glycine modulatory site in rat cultured hippocampal neurons. Biochem Biophys Res Commun 2004;323:416-24.
253. Radad K, Gille G, Moldzio R, Saito H, Rausch WD. Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res 2004;1021:41-53.
254. Bao HY, Zhang J, Yeo SJ, et al. Memory enhancing and neuroprotective effects of selected ginsenosides. Arch Pharm Res 2005;28:335-42.
255. Kennedy DO, Scholey AB, Wesnes KA. Differential, dose dependent changes in cognitive performance following acute administration of a Ginkgo biloba/Panax ginseng combination to healthy young volunteers. Nutr Neurosci 2001;4:399-412.
256. Johnson A, Jiang N, Stuba E. Whole ginseng effects on human response to demands for performance. In: Proceedings of the 3rd International Ginseng Symposium; September 8-10, 1980; Seoul, Korea. Seoul: Korea Ginseng and Tobacco Research Institute; 1980: 244.
257. Moretti R, Torre P, Antonello RM, et al. Neuropsychological evaluation of late-onset post-radiotherapy encephalopathy: a comparison with vascular dementia. J Neurol Sci 2005;229-230:195-200.
258. Dundee JW, Chestnutt WN, Ghaly RG, Lynas AG. Traditional Chinese acupuncture: a potentially useful antiemetic? Br Med J (Clin Res Ed) 1986;293:583-4.
259. Dundee JW, Ghaly RG, Fitzpatrick KT, Abram WP, Lynch GA. Acupuncture prophylaxis of cancer chemotherapy-induced sickness. J R Soc Med 1989;82:268-71.
260. al-Sadi M, Newman B, Julious SA. Acupuncture in the prevention of postoperative nausea and vomiting. Anaesthesia 1997;52:658-61.
261. Schlager A, Offer T, Baldissera I. Laser stimulation of acupuncture point P6 reduces postoperative vomiting in children undergoing strabismus surgery. Br J Anaesth 1998;81:529-32.
262. Lee A, Done ML. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: a meta-analysis. Anesth Analg 1999;88:1362-9.
263. NIH Consensus Development Panel on Acupuncture. NIH consensus conference. Acupuncture. JAMA 1998;280:1518-24.
264. Shen J, Wenger N, Glaspy J, et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: a randomized controlled trial. JAMA 2000;284:2755-61.
265. Roscoe JA, Matteson SE, Morrow GR, et al. Acustimulation wrist bands are not effective for the control of chemotherapy-induced nausea in women with breast cancer. J Pain Symptom Manage 2005;29:376-84.
266. Ezzo J, Vickers A, Richardson MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol 2005;23:7188-98.
267. Thompson JW, Filshie J. Transcutaneous electrical nerve stimulation (TENS) and acupuncture. In: Doyle D, Hanks GWC, MacDonald N, eds. Oxford Textbook of Palliative Medicine, 2nd ed. Oxford, U.K.: Oxford University Press; 1998: 421-37.
268. Filshie J, Redman D. Acupuncture and malignant pain problems. Eur J Surg Oncol 1985;11:389-94.
269. Filshie J. Acupuncture for malignant pain. Acupunct Med 1984;2:12-14.
270. Filshie J, Bolton T, Browne D, Ashley S. Acupuncture and self acupuncture for long-term treatment of vasomotor symptoms in cancer patients - audit and treatment algorithm. Acupunct Med 2005;23:171-80.
271. Alimi D, Rubino C, Pichard-Leandri E, Fermand-Brule S, Dubreuil-Lemaire ML, Hill C. Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial. J Clin Oncol 2003; 21:4120-6.
272. Wong R, Sagar S. Acupuncture treatment for chemotherapy-induced peripheral neuropathy - a case series. Acupunct Med 2006;24:87-91.
273. Lee H, Schmidt K, Ernst E. Acupuncture for the relief of cancer-related pain: a systematic review. Eur J Pain 2005;9:437-44.
274. Barlas P, Ting SL, Chesterton LS, Jones PW, Sim J. Effects of intensity of electroacupuncture upon experimental pain in healthy human volunteers: a randomized, double-blind, placebo-controlled study. Pain 2006;122:81-9.
275. Pomeranz B, Niznik G. Codetron: a new electrotherapy device overcomes the habituation problems of conventional TENS devices. Am J Electromed 1987;2:22-6.
276. Patel M, Gutzwiller F, Paccaud F, Marazzi A. A meta-analysis of acupuncture for chronic pain. Int J Epidemiol 1989;18:900-6.
277. Gadsby JG, Flowerdew MW. Review: transcutaneous electrical nerve stimulation reduces pain and improves range of movement in chronic low-back pain. Evid Based Med 1997;2:107.
278. Ernst E, White AR. Acupuncture for back pain: a meta-analysis of randomized controlled trials. Arch Intern Med 1998;158:2235-41.
279. Ghoname EA, Craig WF, White PF, et al. Percutaneous electrical nerve stimulation for low back pain: a randomized crossover study. JAMA 1999;281:818-23.
280. Blom M, Dawidson I, Angmar-Månsson B. The effect of acupuncture on salivary flow rates in patients with xerostomia. Oral Surg Oral Med Oral Pathol 1992;73:293-8.
281. Blom M, Lundeberg T, Dawidson I, Angmar-Månsson B. Effects on local blood flux of acupuncture stimulation used to treat xerostomia in patients suffering from Sjögren's syndrome. J Oral Rehabil 1993;20:541-8.
282. Talal N, Quinn JH, Daniels TE. The clinical effects of electrostimulation on salivary function of Sjögrens syndrome patients: a placebo controlled study. Rheumatol Int 1992;12:43-5.
283. Blom M, Dawidson I, Fernberg JO, Johnson G, Angmar-Månsson B. Acupuncture treatment of patients with radiation-induced xerostomia. Eur J Cancer B Oral Oncol 1996; 32B:182-90.
284. Blom M, Lundeberg T. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 2000;6:15-24.
285. Rydholm M, Strang P. Acupuncture for patients in hospital-based home care suffering from xerostomia. J Palliat Care 1999;15:20-3.
286. Johnstone PA, Peng YP, May BC, Inouye WS, Niemtzow RC. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 2001;50:353-7.
287. Wong RK, Jones GW, Sagar SM, Babjak AF, Whelan T. A phase I/II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:472-80.
288. Deng G, Hou BL, Holodny AI, Vickers AJ, Cassileth BR. Randomized controlled trial of functional magnetic resonance imaging (fMRI) changes associated with acupuncture at a point used to treat xerostomia versus sham acupuncture or gustatory stimulation [abstract]. In: Society for Integrative Oncology (SIO). Abstracts of the 3rd International Conference; November 9-11, 2006; Boston, MA. Mt. Royal, NJ: SIO; 2006. [Available online at: www.integrativeonc.org/images/2006%20Conference %20Abstracts%20&%20Posters.pdf; cited October 28, 2007]
289. Widerstrom-Noga E, Dyrehag LE, Borglum-Jensen L, Aslund PG, Wenneberg B, Andersson SA. Pain threshold responses to two different modes of sensory stimulation in patients with orofacial muscular pain: psychological considerations. J Orofac Pain 1998;12:27-34.
290. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996;32A:1340-3.
291. Campbell SS, Murphy PJ. Extraocular circadian phototransduction in humans. Science 1998;279:396-9.
292. Glaus A. Fatigue and cachexia in cancer patients. Support Care Cancer 1998;6:77-8.
293. Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer 1998;34:1670-6.
294. Bonta IL. Acupuncture beyond the endorphin concept? Med Hypotheses 2002;58:221-4.
295. Han JS. Acupuncture and endorphins. Neurosci Lett 2004;361:258-61.
296. Han JS. Electroacupuncture: an alternative to antidepressants for treating affective diseases. Int J Neurosci 1986;29:79-92.
297. Roschke J, Wolf C, Muller MJ, et al. The benefit from whole body acupuncture in major depression. J Affect Disord 2000;57:73-81.
298. Smith CA, Hay PPJ. Acupuncture for depression. Cochrane Database Syst Rev 2005;(2):14651858.CD004046.pub2.
299. Yu J, Liu C, Zhang X, Han J. Acupuncture improved cognitive impairment caused by multi-infarct dementia in rats. Physiol Behav 2005;86:434-41.
300. Johnston MF, Yang C, Hui KK, Xiao B, Li XS, Rusiewicz A. Acupuncture for chemotherapy-associated cognitive dysfunction: a hypothesis-generating literature review to inform clinical advice. Integr Cancer Ther 2007;6:36-40.
301. Vickers AJ, Straus DJ, Fearon B, Cassileth BR. Acupuncture for postchemotherapy fatigue: a phase II study. J Clin Oncol 2004;22:1731-5.
302. Ernst E, White AR. Acupuncture as a treatment for temporomandibular joint dysfunction: a systematic review of randomized trials. Arch Otolaryngol Head Neck Surg 1999; 125:269-72.
303. Zhang, Z. Effect of acupuncture on 44 cases of radiation rectitis following radiation therapy for carcinoma of the cervix uteri. J Tradit Chin Med 1987;7:139-40.
304. Yan LS. Treatment of persistent hiccupping with electro-acupuncture at "hiccup-relieving" point. J Tradit Chin Med 1988; 8:29-30.
305. Wong R, Sagar SM. The treatment of persistent yawning with acupuncture. Acupunct Med 2000;18:124-6.
306. Feng R. Relief of oesophageal carcinomatous obstruction by acupuncture. J Tradit Chin Med 1984;4:3-4.
307. Filshie J, Penn K, Ashley S, Davis CL. Acupuncture for the relief of cancer-related breathlessness. Palliat Med 1996;10:145-50.
308. Vickers AJ, Feinstein MB, Deng GE, Cassileth BR. Acupuncture for dyspnea in advanced cancer: a randomized, placebo-controlled pilot trial [ISRCTN89462491]. BMC Palliat Care 2005;4:5.
309. Hammar M, Frisk J, Grimas O, Hook M, Spetz AC, Wyon Y. Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study. J Urol 1999;161:853-6.
310. Tukmachi E. Treatment of hot flushes in breast cancer patients with acupuncture. Acupunct Med 2000;18:22-7.
311. Cumins SM, Brunt AM. Does acupuncture influence the vasomotor symptoms experienced by breast cancer patients taking tamoxifen? Acupunct Med 2000;19:28-9.
312. Fontanarosa PB, Lundberg GD. Alternative medicine meets science. JAMA 1998;280:1618-19.
313. Sagar SM. Unproven cancer therapies. Ann R Coll Physicians Surg Can 1998;31:160.
314. Sagar SM. Alternative views on alternative therapies. CMAJ 1999;160:1697-9.
315. Sagar SM. Restored Harmony: An Evidence-based Approach for Integrating Traditional Chinese Medicine into Complementary Cancer Care. Hamilton, ON: Dreaming DragonFly Communications; 2001.
316. Tagliaferri M, Cohen I, Tripathy D. Complementary and alternative medicine in early-stage breast cancer. Semin Oncol 2001;28:121-34.
317. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998;280:1585-9.